Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

SIMPLE SUMMARY: The ToGA trial has demonstrated, in HER2-expressing patients, that unresectable and advanced gastric cancer, chemotherapy and trastuzumab in combination increase overall survival, even if it is still unclear why after one year the same patients are non-responsive to trastuzumab treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Laterza, Maria Maddalena, Ciaramella, Vincenza, Facchini, Bianca Arianna, Franzese, Elisena, Liguori, Carmela, De Falco, Stefano, Coppola, Paola, Pompella, Luca, Tirino, Giuseppe, Berretta, Massimiliano, Montella, Liliana, Facchini, Gaetano, Ciardiello, Fortunato, de Vita, Ferdinando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150287/
https://www.ncbi.nlm.nih.gov/pubmed/34066144
http://dx.doi.org/10.3390/cancers13102339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150287/
https://www.ncbi.nlm.nih.gov/pubmed/34066144
http://dx.doi.org/10.3390/cancers13102339

Ejemplares similares